Posted by Michael Wonder on 16 Nov 2021
Pfizer seeks emergency use authorisation for novel COVID-19 oral antiviral candidate
16 November 2021 - If approved or authorised, Paxlovid (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2.
Pfizer today announced it is seeking emergency use authorisation of its investigational oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalisations or death.
